Search research articles
Contact Us
Filters
Showing results (111-120 of 128) with videos related to
Page
of 13
Sort By:
Drug Metabolism Reviews
|
September 22, 2023
Biotransformation research advances - 2022 year in review
S Cyrus Khojasteh, Upendra A Argikar, Lionel Cheruzel, et al.
Biorxiv : the Preprint Server for Biology
|
February 27, 2026
Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer
Xin Cheng, Changli Qian, Erica Holdridge, et al.
Communications Medicine
|
May 21, 2024
Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors
Jian Jenny Chen, Melanie Y Vincent, Dale Shepard, et al.
Nature Communications
|
May 4, 2026
Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer
Xin Cheng, Yadong Zhang, Changli Qian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2020
Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial
Paul DiSilvestro, Nicoletta Colombo, Giovanni Scambia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2022
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 23, 2012
Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome
Zhigang C Wang, Nicolai Juul Birkbak, Aedín C Culhane, et al.
The Lancet. Oncology
|
April 16, 2021
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial
Michael Friedlander, Kathleen N Moore, Nicoletta Colombo, et al.
Nature Communications
|
November 3, 2025
Rational design of potent small-molecule SMARCA2/A4 degraders acting via the recruitment of FBXO22
Elisia Villemure, Tom Januario, Mingshuo Zeng, et al.
Molecular Cell
|
December 2, 2021
Quantitative subcellular acyl-CoA analysis reveals distinct nuclear metabolism and isoleucine-dependent histone propionylation
Sophie Trefely, Katharina Huber, Joyce Liu, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 128) with videos related to
Sort By:
Page
of 13
Drug Metabolism Reviews
|
September 22, 2023
Biotransformation research advances - 2022 year in review
S Cyrus Khojasteh, Upendra A Argikar, Lionel Cheruzel, et al.
Biorxiv : the Preprint Server for Biology
|
February 27, 2026
Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer
Xin Cheng, Changli Qian, Erica Holdridge, et al.
Communications Medicine
|
May 21, 2024
Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors
Jian Jenny Chen, Melanie Y Vincent, Dale Shepard, et al.
Nature Communications
|
May 4, 2026
Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer
Xin Cheng, Yadong Zhang, Changli Qian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2020
Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial
Paul DiSilvestro, Nicoletta Colombo, Giovanni Scambia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2022
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 23, 2012
Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome
Zhigang C Wang, Nicolai Juul Birkbak, Aedín C Culhane, et al.
The Lancet. Oncology
|
April 16, 2021
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial
Michael Friedlander, Kathleen N Moore, Nicoletta Colombo, et al.
Nature Communications
|
November 3, 2025
Rational design of potent small-molecule SMARCA2/A4 degraders acting via the recruitment of FBXO22
Elisia Villemure, Tom Januario, Mingshuo Zeng, et al.
Molecular Cell
|
December 2, 2021
Quantitative subcellular acyl-CoA analysis reveals distinct nuclear metabolism and isoleucine-dependent histone propionylation
Sophie Trefely, Katharina Huber, Joyce Liu, et al.
Page
of 13